Printer Friendly

ARMOUR PHARMACEUTICAL COMPANY APPOINTS TWO NEW EXECUTIVES

 ARMOUR PHARMACEUTICAL COMPANY APPOINTS TWO NEW EXECUTIVES
 COLLEGEVILLE, Pa., May 28 /PRNewswire/ -- Armour Pharmaceutical Company, the plasma fractions subsidiary of Rhone-Poulenc Rorer (NYSE: RPR), today announced the appointment of two new executives in key senior positions.
 Zsolt Lavotha is appointed to the position of vice president and general manager, Armour Non-U.S. Markets. In this position, Lavotha will be responsible for managing Armour businesses outside of the United States and Canada. Prior to joining RPR, Lavotha held several senior management positions in sales, marketing, and business development with Pfizer, Inc. Most recently, he was director, Business Operations Development-Europe with Pfizer International. Lavotha is a graduate of Upsala University with a degree in biomedicine and chemistry.
 Lyn Wiesinger is appointed to the position of vice president, Worldwide Marketing, responsible for the development, management and execution of Armour's global marketing programs. Wiesinger joins RPR from Pfizer, Inc., where she has held several senior management positions in marketing, investor relations and strategic planning. Most recently, she managed the development and marketing team for Diflucan(R), a systemic anti-fungal. Wiesinger holds an undergraduate degree from the University of Pennsylvania and an M.B.A. from The Wharton School.
 Armour Pharmaceutical Company, a subsidiary of Rhone-Poulenc Rorer Pharmaceuticals, is a leading manufacturer of high quality plasma derivatives. The company manufactures a full range of plasma derivated therapeutics including Monoclate-P (monoclonal antibody purified Factor VIII), Albuminar, Purimmun, Gamulin and Gammar IV.
 Rhone-Poulenc Rorer is a global pharmaceutical company dedicated to the discovery, development, manufacturing and marketing of human pharmaceuticals. The company reported sales of $3.8 billion and invested $445 million in R&D in 1991.
 /delval/
 -0- 5/28/92
 /CONTACT: Rhone-Poulenc Rorer media relations, 215-454-3871, or investor relations, 215-454-3851/ CO: Armour Pharmaceutical Company; Rhone-Poulenc Rorer ST: Pennsylvania IN: MTC SU: PER


LJ -- PH012 -- 4612 05/28/92 09:45 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 28, 1992
Words:306
Previous Article:CRSS SUBSIDIARY ANNOUNCES FORMATION OF CRSS STRATEGIC CONSULTANTS
Next Article:BENGUET ANNOUNCES RESULTS OF ANNUAL MEETING
Topics:


Related Articles
THE LIPOSOME COMPANY APPOINTS NEW MANUFACTURING EXECUTIVE
AFFINITY BIOTECH APPOINTS TWO BOARD MEMBERS TO NEW SEATS AND APPOINTS NEW DIRECTOR OF ANALYTICAL SCIENCES
BARRY BLOOM TO RETIRE FROM PFIZER; JOHN NIBLACK NAMED EXECUTIVE VICE PRESIDENT -- R&D
CELGENE ELECTS NEW BOARD MEMBER
Synthetech Elects Two New Outside Directors
Schering-Plough Board of Directors Elects Richard Jay Kogan Chairman of Board And CEO, Raul E. Cesan as President and Chief Operating Officer.
Schering-Plough Board of Directors Elects Richard Jay Kogan Chairman of Board And CEO, Raul E. Cesan as President and Chief Operating Officer.
Schering-Plough Board of Directors Elects Richard Jay Kogan Chairman of Board And CEO, Raul E. Cesan as President and Chief Operating Officer.
Schering-Plough Board of Directors Elects Richard Jay Kogan Chairman of Board And CEO, Raul E. Cesan as President and Chief Operating Officer.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters